شبكة المعلومات الجامعية

بسم الله الرحمن الرحيم

شبكة المعلومات الجامعية

التوثيق الالكتروني والميكروفيلم

شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الالكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأفلام قد أعدت دون أية تغيرات

يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of 15-25- c and relative humidity 20-40%

بعض الوثائـــــــق الاصليـــــة تالفـــة

بالرسالة صفحات لم ترد بالاصل

Effect of Hemofiltration on Hemostasis during Open Heart Surgery

Thesis
Submitted in Partial Fulfillment of
M.D. Degree in Clinical and
Chemical Pathology

By
Siham Assem Ali Barakat
M.Sc.(Clin. Path.)

Supervised By

Prof. Dr. Mohammad El Hindi
Professor of Clinical and Chemical Pathology
Banha Faculty of Medicine, Zagazig University

Prof. Dr. Maha Salah Youssef
Professor of Clinical and Chemical Pathology
Banha Faculty of Medicine, Zagazig University

Assist.Prof. Dr. Mohammad Zakaria
Assistant Professor of Pediatrics
Banha Faculty of Medicine, Zagazig University

Assist.Prof. Dr. Laila El Mahrouky
Assistant Professor of Clinical and Chemical Pathology
Banha Faculty of Medicine, Zagazig University

1999

بسم الله الرحمن الرحيم

"وعلمك ما لم تكن تعلم وكان فضل الله عليك عظيماً"

صدق الله العظيم

(سورة النساء آية ١١٣)

Acknowledgement

It is a great a honour to express my deep gratitude and appreciation to ***Professor Dr.Mohammad El Hindi*** , Professor of Clinical and Chemical Pathology , Banha Faculty of Medicine, Zagazig University for his excellent guidance, suggestions and valuable advice .

I am deeply indebted to ***Professor Dr. Maha Salah Youssef*** , Professor of Clinical and Chemical Pathology, Banha Faculty of Medicine , Zagazig University , for her kind supervision, sincere and valuable help, guidance and support throughout the course of this work.

I am also grateful to ***Assistant Professor Dr. Mohammad Zakaria***, Assistant Professor of Pediatrics, Banha Faculty of Medicine, Zagazig University for his sincere help, and cooperation.

I would like also to express my gratitude to ***Assistant Professor Dr Laila El Mahrouky***, Assistant Professor of Clinical and Chemical Pathology, Banha Faculty of Medicine, Zagazig University for her supervision, and helpful guidance.

Lastly but not least I am whole heartedly indebted to my family and colleagues in the Department of Cardiothoracic Surgery and Lab, Ain Shams University, for their perpetual support, assistance and encouragement.

Contents

Introduction and Aim of Work

Review of Literature

Normal Hemostasis 1
- Vascular System 1
- Platelets System 12
- Coagulation Cascade System 23
- Naturally Protective Mechanisms 37

Cardiopulmonary Bypass Inflammatory and Coagulation Response 42
- The Ischaemic Reperfusion Injury 45
- Inflammatory response and Platelet Activation 50
- Coagulation and Fibrinolytic Activation 54

Open Heart Surgery and Blood Transfusion 60

Reduction of Bleeding in Cardiopulmonary Bypass Patients 69

Hemofiltration 72
- Historic Prespective 72
- Hemofiltration and Pediatric Surgery 73
- Basic Physiological Principle 74

Patients and Methods 79

Results 95

Discussion 121

Summary and Conclusion 129

Recommendations 131

References 132

List of Tables

Table (1a)	Comparison between patients age (yrs.), CPB time (min.) values in the control and hemofilter group.	**100**
Table (1b)	Comparison between patients' sex in the control and hemofilter group.	**100**
Table (2a)	Hemoglobin concentration (gm/dl) within the control and hemofilter group.	**101**
Table (2b)	Comparison between hemoglobin concentration (gm/dl) in the control and hemofilter group.	**101**
Table (3a)	Hematocrit (%) within the control and hemofilter group.	**103**
Table (3b)	Comparison between hematocrit (%) in the control and hemofilter group.	**103**
Table (4a)	Platelet count (X $10^3/mm^3$) within the control and hemofilter group.	**105**
Table (4b)	Comparison between platelet counts (X $10^3/mm^3$) in the control and hemofilter group.	**105**
Table (5a)	Prothrombin time (sec.) within the control and the hemofilter group.	**107**
Table (5b)	Comparison between prothrombin time (sec.) in the control and hemofilter group.	**107**
Table (6a)	Activated partial thromboplastin time (sec.) within the control and hemofilter group.	**109**
Table (6b)	Comparison between activated partial thromboplastin time in the control and hemofilter group.	**109**
Table (7a)	Fibrinogen concentration (mg/dl) within the control and hemofilter group.	**111**

Table (7b)	Comparison between fibrinogen concentration (mg/dl) in the control and hemofilter group.	**111**
Table (8)	Fibrinogen degradation products (μg/ml) within the control and hemofilter group.	**113**
Table (9a)	Antithrombin III (%) within the control and hemofilter group.	**114**
Table (9b)	Comparison between antithrombin III (%) in the control and hemofilter group.	**114**
Table (10a)	D-dimer concentration (ng/ml) within the control and hemofilter group.	**116**
Table (10b)	Comparison between D-dimer concentration (ng/ml) in the control and hemofilter group.	**116**
Table (11)	Comparison between the control and hemofilter group as regards blood loss (ml).	**118**
Table (12)	Comparison between both groups as regards ICU stay (day) ,ventilation time (hour) and hospital stay (day).	**119**

List of Figures

Figure (1)	HS-accelerated inhibition by AT III on the surface of endothelial cells.	**5**
Figure (2)	TM- mediated PC activation by AT III, HCII, and PCI on the surface of endothelial cells.	**7**
Figure (3)	Inhibition of F Xa and TF-F VIIa by TFPI on the surface of endothelial cells.	**10**
Figure (4)	Platelet ultrastructure.	**13**
Figure (5)	Platelet function.	**14**
Figure (6)	Bi-directional trafficking across platelet surface	**17**
Figur (7)	Pathways of blood coagulation.	**24**
Figure (8)	Activation pathways of prothrombin.	**32**
Figure (9)	Structure of fibrinogen.	**35**
Figure (10)	Crosslinking of fibrin.	**36**
Figure (11)	Inflammatory response induced by CPB.	**43**
Figure (12)	Rolling, adhesion and aggregation of inflammatory cells on the vascular endothelium.	**49**

Figure (13)	Generation of thrombin activated via either the contact system or the extrinsic release of TF.	**55**
Figure (14)	Possible mechanisms of action of approtenin .	**70**
Figure (15)	Active site blocked F IXa .Effective replacement of F IXa.	**71**
Figure (16)	Ultrafiltration.	**78**
Figure (17)	Placement of ultrafiltration device within the extracorporial circuit.	**78**
Figure (18)	Comparison between hemoglobin concentration (mg/dl) in patients of control and hemofilter group.	**102**
Figure (19)	Comparison between hematocrit % in patients of control and hemofilter group.	**104**
Figure (20)	Comparison between platelet count ($X10^3/mm^3$) in patients of control and hemofilter group.	**106**
Figure (21)	Comparison between prothrombin time values (sec) in patients of control and hemofilter group.	**108**
Figure (22)	Comparison between activated partial thromboplastin time (sec) in patients of control and hemofilter group.	**110**
Figure (23)	Comparison between fibrinogen concentration (mg/dl) in patients of control and hemofilter group.	**112**
Figure (24)	Comparison between antithrombin III % in patients of control and hemofilter group.	**115**
Figure (25)	Comparison between D-dimer concentration (ng/ml) In patients of control and hemofilter group.	**117**

Figure (26) Comparison between patients of control and hemofilter group as regards blood loss (ml). **118**

Figure (27) Comparison between patients of control and hemofilter group as regards ICU and hospital stay (day). **119**

Figure (28) Comparison between patients of control and hemofilter group as regards ventilation time (hour). **120**

List of Abbreviations

α_2AP	α_2 Antiplasmin
APC	Activated protein C
APTT	Activated partial thromboplastin time
AT III	Antithrombin III
B-TG	Beta thromboglobulin
CPB	Cardiopulmonary bypass
DSPG	Dermatan sulfate proteoglycans
EC	Endothelial cells
FDA	Food and Drug Association
FDPs	Fibrinogen degradation products
FFP	Fresh frozen plasma
FPA &B	Fibrinopeptide A & B
GAGs	Glycosaminoglycans
GPs	Glycoproteins
HB	Hemoglobin
HC II	Heparin cofactor
Hct	Hematocrit
HMWK	High molecular weight kininogen
HSPG	Heparan sulfate proteoglycans
ICU	Intensive care unit
IL	Interleuken
IR	Ischaemic reperfusion
OCS	Open canalicular system
PAI	Plasminogen activator inhibitor
PC	Protein C
PCI	Protein C inhibitor
PCR	Protein C receptor
PDFG	Platelet derived growth factor
PF4	Platelet factor 4
PS	Protein S
rPF_4	recombinant Platelet factor $_4$
SCCS	Surface connected canalicular system
TAT	Thrombin antithrombin III complex
TF	Tissue factor
TFPI	Tissue factor pathway inhibitor
TM	Thrombomodulin
TNF	Tumour necrosis factor